Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Candesartan Cilexetil Drug Market Poised To Hit $2.15 Billion By 2030 With A 5.5% CAGR
The candesartan cilexetil drug market size has demonstrated significant growth in recent years. It is projected to increase from $1.65 billion in 2025 to $1.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.4%. The expansion observed in the historical period can be ascribed to several factors, including a rising prevalence of hypertension, the clinical effectiveness of ARBs, a movement away from ACE inhibitors, the broadening of cardiovascular treatment guidelines, and an expanding aging population.
The candesartan cilexetil drug market is anticipated to experience substantial growth over the next few years, with projections indicating it will reach $2.15 billion by 2030, advancing at a compound annual growth rate (CAGR) of 5.5%. This expansion during the forecast period is primarily driven by factors such as an increase in chronic cardiovascular diseases, the broader penetration of generic drugs, a rise in the adoption of combination medications, improved access in developing regions, and a greater focus on preventive cardiovascular care. Prominent trends for this period include the expanding use of angiotensin receptor blockers in treating hypertension, a growing number of prescriptions for managing heart failure, an escalating demand for generic antihypertensive drugs, the development of more combination therapy formulations, and enhanced patient compliance achieved through once-daily dosing.
Get A Free Sample Report With In-Depth Market Insights:
Candesartan Cilexetil Drug Market Growth Factors: What’s Supporting Expansion?
The increasing occurrence of hypertension is anticipated to drive expansion of the candesartan cilexetil drug market moving forward. Hypertension, identified as high blood pressure, signifies a medical state where the blood’s force against artery walls remains consistently elevated, typically defined as a reading of 130/80 mmHg or higher. The widespread nature of hypertension arises from progressively unhealthy lifestyle choices, such as inadequate diet, insufficient physical activity, and high levels of stress. Candesartan cilexetil drug aids in managing hypertension by obstructing the activity of angiotensin II, a hormone responsible for constricting blood vessels, thereby relaxing them and decreasing blood pressure. As an illustration, in October 2024, reports from the Centers for Disease Control and Prevention, a US-based government agency, showed that from August 2021 to August 2023, hypertension prevalence saw a marked increase, climbing by 124.48% in the transition from the 18–39 age group to the 40–59 age group, and by 36.38% as it shifted from the 40–59 age group to individuals aged 60 and older. Consequently, the rising burden of hypertension is boosting demand within the candesartan cilexetil drug market.
Candesartan Cilexetil Drug Market Segmentation: How Does The Market Break Down By Category?
The candesartan cilexetil drug market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Other Product Types
2) By Indication: Hypertension, Heart Failure, Diabetic Nephropathy, Left Ventricular Hypertrophy
3) By Dosage Strength: 4 MG, 8 MG, 16 MG, 32 MG
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Healthcare Facilities
5) By Application: Adult, Children And Adolescent
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Dispersible Tablets, Chewable Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gelatin Capsules, Modified-Release Capsules
3) By Other Product Types: Oral Suspensions, Injectable Formulations, Combination Drug Formulations
Candesartan Cilexetil Drug Market Industry Trends: What’s Reshaping Demand?
Leading companies in the candesartan cilexetil drug market are prioritizing the creation of advanced formulations, such as therapies for high blood pressure, combined treatments with other antihypertensive medications, and prolonged-release versions, all designed to improve patient compliance and enhance treatment efficacy. Managing hypertension involves utilizing medications, lifestyle adjustments, and various other interventions aimed at reducing and controlling elevated blood pressure, thereby decreasing the likelihood of complications like heart disease, stroke, and kidney damage. For example, in March 2025, Scienture Inc., a pharmaceutical firm based in the US, obtained approval from the US Food & Drug Administration (USFDA) for its New Drug Application (NDA) for SCN-102, introduced as Arbli, a losartan potassium oral suspension (10 mg/mL). This angiotensin II receptor blocker (ARB) formulation presents a viable option for patients who experience difficulty swallowing tablets, particularly among pediatric and geriatric demographics. The introduction of this product demonstrates the rising appeal of alternative dosage forms within the antihypertensive market and signifies a transition towards customized, patient-focused drug delivery solutions.
Candesartan Cilexetil Drug Market Competitive Overview And Top Companies
Major companies operating in the candesartan cilexetil drug market are Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Torrent Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Oubari Pharmaceutical Co.
View The Full Candesartan Cilexetil Drug Market Report:
Candesartan Cilexetil Drug Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the candesartan cilexetil drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candesartan cilexetil drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
